HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups.

Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.

While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.

Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.

In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.

The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.

Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estim
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:3/31/2015)... Burns Engineering announces 3-Day Quick Ship on S01 ... Beverage, Pharmaceutical and Biotech markets. These field proven sensors conform ... now available as part of Burns’ Quick Ship Program to ... and S03 with 1/8” and 1/4” diameters respectively are ... process lines 1/4” and larger. Sensors are available in ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market ... Type (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, ... analyzes and studies the major market drivers, restraints, ... and the Rest of the world (RoW). ... to reach $3.58 billion by 2019 from $2.4 ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 ... that specializes in providing online solutions to ... today it has achieved full accreditation for ... Network Accreditation Program (HNAP) from the Electronic ... EHNAC’s HNAP accreditation runs in two-year increments ...
(Date:3/31/2015)... March 31, 2015 Diane Blackburn-Zambetti ... at the Mesothelioma Applied Research Foundation (Meso Foundation). ... and Your Health” at the BoRit Asbestos Superfund ... April. This program will discuss anatomy, six types ... asbestos diseases, symptoms, treatments, prevention and proper communication ...
(Date:3/31/2015)... Nashville, TN (PRWEB) March 31, 2015 ... TN welcomes warmer temperatures and sunshine; however, it's important to ... irreversible eye damage. Experts say more than 90 ... a few precautions and wearing safety glasses. Dr. Shofner shares ... damage this season. , 1) Yard Work. While using a ...
Breaking Medicine News(10 mins):Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3Health News:Mesothelioma Foundation to speak at BoRit Asbestos Superfund Citizen Advisory Group Meeting 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 3Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 4
(Date:3/31/2015)... March 31, 2015  On May 2, 2015 ... in Santa Monica, CA ... Therapies for Malignant Pleural Mesothelioma (MPM), a rare ... asbestos and commonly affects the lining of the ... UCLA and the Pacific Mesothelioma Center (PMC). ...
(Date:3/31/2015)... 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; ... specializes in developing safer, more effective cannabis-based therapies, ... Anderson , Ph.D., to its Scientific Advisory Board.  ... brings significant drug discovery and development expertise to ... organic chemist by training with more than 30 ...
(Date:3/31/2015)... TEMPLE, Texas , March 31, 2015   ... its operational transformation is complete and the company has ... guidelines. "Our goal as a company is ... CEO Travis Leeah . "Meeting the new regulations ... dedicated staff. We,re embracing the future of our industry, ...
Breaking Medicine Technology:Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 2Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 3Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 4InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3
Cached News: